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Abstract
Introduction: There is a paucity of data about the clinical characteristics that help identify patients at high risk of
influenza infection upon ICU admission. We aimed to identify predictors of influenza infection in patients admitted
to ICUs during the 2007/2008 and 2008/2009 influenza seasons and the second wave of the 2009 H1N1 influenza
pandemic as well as to identify populations with increased likelihood of seasonal and pandemic 2009 influenza
(pH1N1) infection.
Methods: Six Toronto acute care hospitals participated in active surveillance for laboratory-confirmed influenza
requiring ICU admission during periods of influenza activity from 2007 to 2009. Nasopharyngeal swabs were
obtained from patients who presented to our hospitals with acute respiratory or cardiac illness or febrile illness
without a clear nonrespiratory aetiology. Predictors of influenza were assessed by multivariable logistic regression
analysis and the likelihood of influenza in different populations was calculated.
Results: In 5,482 patients, 126 (2.3%) were found to have influenza. Admission temperature ≥38°C (odds ratio (OR)
4.7 for pH1N1, 2.3 for seasonal influenza) and admission diagnosis of pneumonia or respiratory infection (OR 7.3 for
pH1N1, 4.2 for seasonal influenza) were independent predictors for influenza. During the peak weeks of influenza
seasons, 17% of afebrile patients and 27% of febrile patients with pneumonia or respiratory infection had influenza.
During the second wave of the 2009 pandemic, 26% of afebrile patients and 70% of febrile patients with
pneumonia or respiratory infection had influenza.
Conclusions: The findings of our study may assist clinicians in decision making regarding optimal management of
adult patients admitted to ICUs during future influenza seasons. Influenza testing, empiric antiviral therapy and
empiric infection control precautions should be considered in those patients who are admitted during influenza
season with a diagnosis of pneumonia or respiratory infection and are either febrile or admitted during weeks of
peak influenza activity.
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Introduction
The 2009 H1N1 influenza pandemic had a substantial
effect on ICUs [1] in that pandemic 2009 influenza
(pH1N1) infection was associated with severe hypoxe-
mia, multisystem organ failure, requirements for pro-
longed mechanical ventilation and the need for rescue
therapies [2-5].
Many observational cohort studies, both from the
2009 pandemic and of seasonal influenza pre-pandemic,
have found that antiviral therapy for influenza is asso-
ciated with significantly improved outcomes, particularly
when it is initiated within 48 hours of the onset of
symptoms [6-8]. Optimal management of severe influ-
enza thus depends on the ability to recognize those
patients admitted to the ICU who require empiric ther-
apy for influenza pending the results of diagnostic test-
ing. However, data about clinical characteristics that
help to identify patients at high risk of influenza infec-
tion upon hospital or ICU admission during influenza
season are sparse [9,10]. The aim of this study was to
identify populations of patients with increased probabil-
ities of influenza infection among subjects admitted to
ICUs during the 2007/2008 and 2008/2009 influenza
seasons as well as the second wave of the 2009 H1N1
influenza pandemic.
Materials and methods
Setting and manoeuvre
The Toronto Invasive Bacterial Diseases Network
(TIBDN) is a collaborative network of microbiology
laboratories, infection control practitioners and public
health departments that performs population-based sur-
veillance for infectious diseases in south-central Ontario
[11-13]. Six acute care hospitals from the TIBDN parti-
cipated in active surveillance for laboratory-confirmed
influenza requiring ICU admission during the 2007/2008
and 2008/2009 influenza seasons, and three of these
hospitals performed active surveillance during the sec-
ond wave of the pH1N1 influenza pandemic. All admis-
sions to adult medical or medical/surgical ICUs were
included.
Prior to the 2007/2008 influenza season, attending
physicians agreed that, during influenza seasons, naso-
pharyngeal (NP) swabs were clinically indicated in
patients requiring ICU admission who presented with
any acute respiratory or cardiac illness (independent of
body temperature) or in patients with any febrile illness
without a clear, nonrespiratory aetiology. During each
influenza season, study staff screened all admissions
daily and suggested orders for NP swabs (if they had
not already been ordered) from all patients with any
acute cardiac or respiratory illness or any febrile illness
without a clear nonrespiratory source. Demographic and
medical information was collected from each patient by
chart review. Fever upon ICU admission was defined as
being present if the first body temperature measured
after ICU admission was ≥38.0°C, and the diagnosis was
defined as recorded in each chart. Respiratory symptoms
were defined as any upper or lower respiratory symp-
toms such as coryza, cough, wheezing or shortness of
breath. NP swabs were tested for the presence of influ-
enza by PCR and viral culture at the Ontario Public
Health Laboratory. Some specimens were also tested by
direct fluorescent antigen detection (DFA) or enzyme
immunoassay (EIA) at individual hospitals.
For the purposes of the study, influenza season was
defined as starting when the proportion of positive
influenza tests among specimens submitted to the
Ontario Public Health Laboratory for viral testing was
>5% for two consecutive weeks and as ending when the
proportion of positive tests was <5%. The peak season
was a priori defined as any week in which the propor-
tion of submitted specimens yielding influenza was
>15% [10].
Statistical analyses
Data were double-entered, cleaned and analyzed using
SAS version 9.1 software for PC (SAS Institute, Cary,
NC, USA). Data were analyzed for all patients who were
tested for influenza infection. Differences in medians
were analyzed using the Wilcoxon rank-sum test or the
Kruskal-Wallis test, and differences in group proportions
were assessed using a c2 test or Fisher’s exact test as
appropriate. We performed multivariable logistic regres-
sion analyses to evaluate independent predictors of seaso-
nal and pandemic H1N1 influenza. The variables ‘age ≥65
years’, ‘temperature ≥38.0°C upon admission’, ‘admitting
diagnosis respiratory infection’, ‘admitting diagnosis
respiratory failure’ and ‘week with >15% specimens posi-
tive’ were considered for inclusion in multivariable mod-
els based on clinical judgment and previously published
literature [10] in a manner that minimized the Akaike
Information Criterion, with final models representing
those that best balanced parsimony and fit [14]. The Hos-
mer-Lemeshow Goodness-of-Fit Test was used to assess
model fit. The limited number of outcomes was factored
in when building the models to prevent overfitting. Like-
lihoods were calculated as binomial proportions with
95% confidence intervals. Two-sided P values < 0.05 were
considered statistically significant.
Ethics approval
The study was approved by the Research Ethics Boards
of all participating hospitals. Written informed consent
was obtained as required from all participants or their
authorized representatives.
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Results
Influenza seasons
The influenza season in Toronto in 2007/2008 was
bimodal, with a first season beginning on 16 December
2007 (week 51) and ending on 2 February 2008 (week 5)
and a second season beginning on 24 February 2008
(week 9) and ending on 17 May 2008 (week 20) (Figure
1) [15]. Influenza activity was predominantly influenza
A(H1N1) during the first season and mixed influenza A
(H3N2) and influenza B during the second season. The
2008/2009 influenza season began on 18 January 2009
(week 3) and ended on 25 April 2009 (week 16), with
influenza B, influenza A(H1N1) and influenza A(H3N2)
circulating [16]. The second wave of the 2009 H1N1
pandemic started on 11 October 2009 (week 41) end
ended on 5 December 2009 (week 48). Influenza activity
was almost exclusively pH1N1 [17].
Results of surveillance
During the 2007/2008 and 2008/2009 influenza seasons
and the second wave of the 2009 H1N1 pandemic, a
total of 5,462 patients were admitted to participating
ICUs. Among these patients, 2,416 patients were tested
for influenza and 2,360 (97.7%) met the eligibility cri-
teria for testing (Figure 2). Compliance with testing dif-
fered among the three influenza seasons (90.4% of
eligible patients tested during the 2009 H1N1 influenza
pandemic, 89.4% during the 2008/2009 influenza season
and 63.0% during the 2007/2008 influenza season; P <
0.001) and among the six study hospitals (proportion of
eligible patients tested ranging from 63.9% to 90.4%; P <
0.001). Specimens from eligible patients were more
likely to be submitted if the patient was febrile (80.2%
vs. 74.6%; P = 0.035) or reported respiratory symptoms
upon admission (78.0% vs. 73.3%; P = 0.006), if the
patient was >65 years of age (76.7% vs. 72.4%; P =
0.007), if admission did not occur during peak influenza
weeks (77.6% vs. 71.8%; P < 0.001) and if the admission
diagnosis was ‘pneumonia’, ‘other respiratory infection’,
‘asthma exacerbation’, ‘chronic obstructive pulmonary
disease (COPD) exacerbation’ or ‘respiratory failure’
(82.7% vs. 72.9%; P < 0.001).
A total of 126 patients (5.2% of those tested) were
identified as being infected with influenza. During the
2007/2008 influenza season, 54.3% (38 of 70) of isolates
obtained were influenza A (Figure 2). Seven influenza A
isolates were subtyped: two (28.6%) were influenza A
(H1N1) and five (71.4%) were influenza A(H3N2). Simi-
larly, 63.0% (17 of 27) of isolates obtained during the
2008/2009 influenza season were influenza A. Fifteen of
these were subtyped: three (20.0%) were influenza A
(H1N1) and twelve (80.0%) were influenza A(H3N2). All
29 influenza isolates identified during the 2009 pan-
demic were subtyped and confirmed to be pH1N1.
DFA tests were positive for influenza in 2.6% (13 of
492) of tests submitted, EIAs were positive for influenza
in 1.4% (18 of 1,255), viral cultures were positive for
influenza in 2.8% (39 of 1,381) and PCRs were positive
for influenza in 4.9% (110 of 2,263). Among patients
with at least one positive test for influenza, DFA results
were positive in 68.4% (13 of 19), EIA results were posi-
tive in 29.0% (18 of 62), viral culture results were posi-
tive in 50.6% (39 of 77) and PCR results were positive in
97.3% (110 of 113).
Figure 1 Comparison of influenza activity by laboratory surveillance in Ontario. Data are expressed as the percentage of specimens
submitted to reference virology laboratories yielding influenza, 2007/08 and 2008/09 influenza seasons and second wave of the 2009 H1N1
influenza pandemic (light grey bars: influenza B; dark grey bars: influenza A), as well as the corresponding number of patients admitted to
participating ICUs with influenza (black line).
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Patient characteristics
The characteristics of patients with influenza admitted
during the 2007/2008 and 2008/2009 influenza seasons
and the second wave of the 2009 influenza pandemic
are shown in Tables 1 and 2. Compared to the 2007/
2008 and 2008/2009 influenza seasons, patients requir-
ing ICU admission due to pH1N1 were more likely to
be <65 years of age (23 of 29 (79.3%) vs. 30 of 97
(30.9%); P < 0.001) and more likely to be admitted with
a diagnosis of ‘pneumonia’ or ‘other respiratory
5,462 ICU admissions
2,627 patients admitted in the 
2007/08 influenza season
70 (6.4%) positive
38 influenza A
32 influenza B
1,097 patients tested
2,304 patients admitted in the
2008/09 influenza season
27 (2.5%) positive
17 influenza A
10 influenza B
1,074 patients tested
531 patients admitted during the 
2009 H1N1 pandemic
29 (11.8%) positive
29 influenza A(pH1N1)
245 patients tested
Figure 2 Study subjects. Flowchart of study subjects requiring admission to ICUs in Toronto during the 2007/08 and 2008/09 influenza seasons
and the second wave of the 2009 H1N1 influenza pandemic.
Table 1 Characteristics of patients admitted to ICUsa
Characteristics Influenza-positive/total, n (%)
2007/2008 and 2008/2009 influenza seasons 2009 H1N1 pandemic, second wave
Total number of patients 97/2,171 (4.5) 29/245 (11.8)
Gender
Males 50/1,197 (4.2) 19/127 (15.0)
Females 46/972 (4.7) 10/118 (8.5)
Age, years
All patients, median (IQR) 72.0 (59.4 to 80.5) 67.5 (52.8 to 79.7)
18 to 44 6/168 (3.6) 9/35 (25.7)
45 to 64 24/596 (4.0) 14/78 (18.0)
65 to 84 54/1,147 (4.7) 6/107 (5.6)
≥85 13/260 (5.0) 0/25 (0.0)
Admitted from long-term care facility 7/95 (7.4) 4/13 (30.8)
Temperature on admission, °C
All patients, years, median (IQR) 36.6 (36.0 to 37.2) 36.7 (36.2 to 37.5)
<38.0°C 74/1,964 (3.8) 18/217 (8.3)
≥38.0°C 23/207 (11.1) 11/28 (39.3)
Respiratory symptoms upon hospital admission
Absent 9/628 (1.4) 1/55 (1.8)
Present 87/1,449 (6.0) 27/184 (14.7)
Admission diagnosis
Respiratory infectionb 34/298 (11.4) 17/49 (34.7)
Respiratory failurec 22/212 (10.4) 3/25 (12.0)
Sepsis/fever 4/101 (4.0) 2/15 (13.3)
Any cardiac diagnosis 26/939 (2.8) 3/52 (5.8)
aIQR: interquartile range; b’pneumonia’ and ‘other respiratory infection’; c’chronic obstructive pulmonary disease exacerbation’, ‘asthma exacerbation’ and
‘respiratory failure’.
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infection’ (17 of 29 (58.6%) vs. 34 of 97 (35.1%); P =
0.023). The proportion of males, febrile patients,
patients presenting with respiratory symptoms, patients
admitted from long-term care facilities and patients
admitted with other diagnoses among patients with
influenza infection did not differ between the 2007/2008
and 2008/2009 influenza seasons and the 2009 influenza
pandemic. Analyses according to influenza subtype (sea-
sonal influenza A vs. influenza B vs. pH1N1) revealed
statistically significant differences with regard to patient
age and admission temperature (Table 2). Analyses
according to seasonal influenza A subtypes (influenza A
(H1N1) vs. influenza A(H3N2)) could not be performed
due to the low numbers of subtyped isolates.
Predictors of seasonal and pandemic (H1N1) 2009
influenza infection in patients admitted to ICUs
In multivariable analysis, body temperature ≥38.0°C and
an admission diagnosis of ‘pneumonia/other respiratory
infection’ were independently associated with both sea-
sonal and pH1N1 influenza (Table 3). An admission
diagnosis of ‘COPD exacerbation/asthma exacerbation/
respiratory failure’ independently predicted seasonal
influenza but not pH1N1 infection. Of note, the lack of
predictive ability of this variable for pH1N1 was inde-
pendent of patient age. Age <65 years was indepen-
dently associated with pandemic (H1N1) 2009 influenza
but not with seasonal influenza.
Percentage of patients with seasonal and pandemic
(H1N1) 2009 influenza in different patient populations
Table 4 depicts the percentage of patients with seasonal
influenza and pH1N1 in various patient populations.
The percentage of patients with seasonal influenza was
elevated sixfold above baseline (baseline proportion of
seasonal influenza during the 2007/2008 and 2008/2009
influenza seasons = 0.045) in febrile patients admitted
with ‘pneumonia’, ‘other respiratory infection’, asthma
exacerbation’, ‘COPD exacerbation’ or ‘respiratory fail-
ure’ during weeks of peak influenza activity. In relation
to baseline (baseline proportion of pH1N1 during the
second wave of the 2009 influenza pandemic = 0.118),
the percentage of patients with pH1N1 was elevated
more than twofold in afebrile patients admitted with
‘pneumonia’ or ‘other respiratory infection’ and more
than fivefold if these patients were admitted with a fever
≥38.0°C. However, a considerable fraction of patients
with influenza were not in high-risk groups, particularly
in the case of seasonal influenza. During influenza sea-
sons, patients with ‘pneumonia’, ‘other respiratory infec-
tion’, asthma exacerbation’, ‘COPD exacerbation’ or
‘respiratory failure’ admitted during peak weeks com-
prised only 39% of all patients with influenza. During
the pandemic, patients with an admission diagnosis of
‘pneumonia’ or ‘other respiratory infection’ comprised
59% of all patients with influenza (Table 4).
Discussion
The findings of our study may assist clinicians in deci-
sion making regarding influenza testing and empiric
antiviral treatment of adult patients admitted to ICUs
during future influenza seasons. In prospective surveil-
lance for laboratory-confirmed influenza infection in
patients admitted to the ICUs of six hospitals in Tor-
onto during the 2007/2008 and 2008/2009 influenza sea-
sons and to the ICUs of three hospitals during the
second wave of the 2009 H1N1 influenza pandemic,
admission body temperature ≥38.0°C, admission
Table 2 Characteristics of influenza-positive patients admitted to ICUsa
Characteristics Influenza A (seasonal) (n = 55) Influenza B (n = 42) Pandemic H1N1 (n = 29) P value
Male gender, n (%) 26 (47.3) 24 (58.5) 19 (65.5) 0.24
Median age, years (IQR) 77.6 (63.7 to 83.6) 73.3 (57.2 to 80.8) 50.1 (43.6 to 61.9) <0.001
18 to 44, n (%) 4 (7.3) 2 (4.8) 9 (31.0) 0.001
45 to 64, n (%) 10 (18.2) 14 (33.3) 14 (48.3) 0.015
65 to 84, n (%) 34 (61.8) 20 (47.6) 6 (20.7) 0.002
≥85, n (%) 7 (12.7) 6 (14.3) 0 (0.0) 0.09
Median admission temperature, °C (IQR) 37.1 (36.4 to 37.7) 36.7 (36.1 to 37.8) 37.7 (37.3 to 38.2) 0.004
>38.0°C, n (%) 13 (23.6) 10 (23.8) 11 (37.9) 0.32
Respiratory symptoms, n (%) 51 (92.7) 36 (87.8) 27 (96.4) 0.44
Admission diagnosis
Respiratory infectionb 18 (32.7) 16 (38.0) 17 (58.6) 0.06
Respiratory failurec 11 (20.0) 11 (26.2) 3 (10.3) 0.26
Sepsis 3 (5.5) 1 (2.4) 2 (6.9) 0.65
Cardiac 16 (29.1) 10 (23.8) 3 (10.3) 0.15
aIQR: interquartile range; b’pneumonia’ and ‘other respiratory infection’; c’chronic obstructive pulmonary disease exacerbation’, ‘asthma exacerbation’ and
‘respiratory failure’.
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diagnosis of ‘pneumonia/other respiratory infection’ or
‘COPD/asthma exacerbation/respiratory failure’ and
admission during weeks of peak influenza activity were
independent predictors for seasonal influenza. Overall,
27% of patients meeting all three criteria had labora-
tory-confirmed influenza infection. Age <65 years,
admission body temperature ≥38°C and admission diag-
nosis of ‘pneumonia/other respiratory infection’ were
predictive for pH1N1: 70% of patients with all three
characteristics who were admitted during the second
wave of the 2009 patient had pH1N1 infection.
An increasing number of studies suggest that specific
antiviral therapy is effective in reducing the morbidity
and mortality associated with influenza [18-21], and cur-
rent guidelines for both seasonal and pandemic influ-
enza recommend the treatment of patients requiring
hospitalization for influenza [6,7,22]. However, it is also
clear that antiviral therapy is more effective when
started in the early stages of infection [22-28]. Thus,
optimal management of patients dictates the use of
empiric therapy, and understanding the pretest probabil-
ity of infection is necessary for its rational use. The
Table 4 Proportion of subjects with influenza in different populations of screened patients requiring admission to
ICUsa
Influenza
season
Age Admission diagnosis Admission
temperature
Timing
during
season
Proportion with
influenza (95% CI)
Proportion of total
influenza cases
Proportion of
patients screened
2007/2008 and
2008/2009
Any Respiratory infectionb or
respiratory failurec
≥38°C Peak weeks 0.27 (0.15 to 0.43) 0.124 0.020
<38°C Peak weeks 0.17 (0.11 to 0.24) 0.268 0.071
≥38°C Early or late
weeks
0.12 (0.04 to 0.26) 0.052 0.019
<38°C Early or late
weeks
0.05 (0.03 to 0.08) 0.134 0.124
2009/2010
H1N1
pandemic
Any Respiratory infectionb ≥38°C Any time 0.70 (0.35 to 0.93) 0.241 0.041
<38°C Any time 0.26; 0.13 to 0.42) 0.345 0.159
aOR: odds ratio; 95% CI: 95% confidence interval; b’pneumonia’ and ‘other respiratory infection’; cincludes ‘chronic obstructive pulmonary disease exacerbation’,
‘asthma exacerbation’ and ‘respiratory failure’.
Table 3 Predictors of influenza infection in adult patients admitted to ICUsa
Univariable analysis Multivariable analysisb
Predictor Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Seasonal influenza A and B (2007/2008 and 2008/2009)
Age ≥65 years 1.2 (0.8 to 1.9) 0.37 1.2 (0.8 to 1.9) 0.37
Female gender 1.1 (0.8 to 1.7) 0.53 - -
Temperature ≥38.0°C upon admission 3.2 (2.0 to 5.2) <0.001 2.3 (1.4 to 3.9) 0.002
Respiratory symptoms upon admission 4.4 (2.2 to 8.8) <0.001 - -
Admission diagnosis
Respiratory infectionc 3.7 (2.4 to 5.7) <0.001 4.2 (1.6 to 3.7) <0.001
Respiratory failured 2.9 (1.8 to 4.8) <0.001 4.2 (2.6 to 6.9) <0.001
Week with >15% positive specimens 2.6 (1.7 to 3.9) <0.001 2.5 (1.6 to 3.7) <0.001
Pandemic 2009 H1N1 influenza
Age ≥65 years 0.2 (0.1 to 0.5) <0.001 0.5 (0.3 to 0.8) 0.004
Female gender 0.5 (0.2 to 1.2) 0.12 - -
Temperature ≥38.0°C upon admission 7.2 (2.9 to 17.6) <0.001 4.7 (1.7 to 13.6) 0.004
Respiratory symptoms upon admission 9.3 (1.2 to 70.0) 0.009 - -
Admission diagnosis - -
Respiratory infectionc 8.1 (3.5 to 18.6) <0.001 7.3 (3.0 to 18.1) <0.001
Respiratory failured 1.1 (0.3 to 3.8) 0.92 - -
Week with >15% positive specimens 1.4 (0.5 to 4.2) 0.57 - -
a95% CI: 95% confidence interval. bVariables included in the final model for seasonal and pandemic 2009 H1N1 influenza, respectively, are those where odds
ratios and P values are reported in the multivariable analysis. The Akaike Information Criterion values for the final model of seasonal and pandemic 2009 H1N1
influenza, respectively, were 721.4 and 140.0. c’Pneumonia’ and ‘other respiratory infection’. d’Chronic obstructive pulmonary disease exacerbation’, ‘asthma
exacerbation’ and ‘respiratory failure’.
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differences between the positive predictive value for
influenza in patients in peak and off-peak influenza
weeks during influenza seasons emphasize the need for
intensivists to know whether influenza is circulating in
their area and where they are in each “season” when
deciding on testing and treatment for influenza. As a
rule of thumb, influenza seasons last from 10 to 16
weeks, with peak weeks being the central 4 to 6 weeks.
The 2007/2008 influenza season in Toronto was an
exception. The onset of the season varies by year and by
geographic region within countries and is now usually
declared locally by public health units in North America.
The identification of patients shedding influenza virus
is also important for infection prevention, especially in
ICUs, where influenza outbreaks may be fatal [29,30].
Hospital influenza outbreaks are not uncommon [31],
and expert opinion suggests that additional precautions
for patients admitted with influenza are an important
element of control of transmission of influenza in ICUs
[22,32,33]. Our data support the implementation of
additional precautions empirically until influenza is
ruled out for all patients admitted with pneumonia or
other respiratory infection if they are febrile or are
admitted during weeks of peak influenza activity.
RT-PCR is the only diagnostic test with adequate per-
formance characteristics for the diagnosis of influenza in
adult patients requiring hospital admission [9,22]. As
shown previously by other groups, we have confirmed
that RT-PCR is more sensitive than viral culture or DFA
for rendering an influenza diagnosis, and these tests are,
in turn, more sensitive than commercially available
rapid influenza tests (that is, EIA) [34-36].
There are a number of limitations to our study. First,
sampling from three years in a single geographic area
may limit the generalizability of our results. We mini-
mized selection bias by applying broad inclusion criteria
for testing: All patients who presented with acute
respiratory or cardiac illness or with febrile illness with-
out clear nonrespiratory aetiology were eligible for
inclusion. However, only 75% of eligible patients were
tested for influenza, suggesting that the proportion of
patients actually infected might be higher than our esti-
mate. Data collection by chart review limited the num-
ber of risk factors considered, including differences that
might have been found between vaccinated and unvacci-
nated patients. In addition, rather than individual speci-
fic respiratory symptoms (for example, cough, shortness
of breath), we assessed only respiratory symptoms over-
all. However, the factors we identified were selected to
be easily available for all patients and have the value of
simplicity. Finally, it has previously been shown that
patients who are admitted to the hospital with influenza
infection do not constitute a homogeneous group [37].
The proportion of patients who need specific antiviral
therapy to control influenza infection is unknown, in
contrast to those who are able to control viral replica-
tion but have complications as a result of influenza.
There is a need for further study to define the potential
of antiviral therapy and the causes of hospitalization due
to influenza.
Conclusions
Among those adult patients who are admitted to the
ICU during influenza season with a diagnosis of pneu-
monia or respiratory infection and who are either febrile
or admitted during weeks of peak influenza activity, the
probability of influenza infection may be high enough to
warrant consideration of influenza testing, empiric anti-
viral therapy and/or empiric infection control precau-
tions. However, although our simple rules may result in
improved identification of patients with influenza infec-
tion, a significant proportion of patients who present
without these characteristics will still be missed and our
understanding of which patients will benefit from treat-
ment remains incomplete. These persisting difficulties
highlight the need for further research to enable better
identification of patients admitted with atypical presen-
tations, to understand when patients with influenza are
infectious and to clarify which patients will benefit from
antiviral therapy.
Key messages
• Optimal management of severe influenza depends on
the ability to recognize those patients admitted to the
ICU who require empiric therapy and additional precau-
tions for influenza pending the results of diagnostic
testing.
• Influenza testing, empiric antiviral therapy and
empiric infection control precautions should be consid-
ered in the small proportion of patients admitted during
influenza season with a diagnosis of pneumonia or
respiratory infection and who are either febrile or
admitted during weeks of peak influenza activity.
• Although identification of patients may be improved
with the application of this simple rule, a significant
proportion of patients with influenza infection will be
missed. Further research is needed with regard to strate-
gies for improved identification of influenza patients
admitted with atypical presentations.
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